Comment
doi: 10.1056/NEJMc1908492.
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. Reply
Affiliations
- PMID: 31509690
- DOI: 10.1056/NEJMc1908492
Item in Clipboard
Comment
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. Reply
N Engl J Med.
.
No abstract available
Comment on
-
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.N Engl J Med. 2019 Sep 12;381(11):e23. doi: 10.1056/NEJMc1908492. N Engl J Med. 2019. PMID: 31509689 No abstract available.
Similar articles
-
Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium.Lancet. 1999 May 29;353(9167):1843-7. doi: 10.1016/s0140-6736(98)11467-8. Lancet. 1999. PMID: 10359410 Clinical Trial.
-
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.N Engl J Med. 2019 Sep 12;381(11):e23. doi: 10.1056/NEJMc1908492. N Engl J Med. 2019. PMID: 31509689 No abstract available.
-
Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention.Clin Infect Dis. 2015 Oct 15;61(8):1322-7. doi: 10.1093/cid/civ464. Epub 2015 Jun 16. Clin Infect Dis. 2015. PMID: 26082504 Free PMC article. Clinical Trial.
-
Rifapentine for latent tuberculosis infection treatment in the general population and human immunodeficiency virus-positive patients: summary of evidence.Rev Soc Bras Med Trop. 2015 Sep-Oct;48(5):507-13. doi: 10.1590/0037-8682-0156-2014. Rev Soc Bras Med Trop. 2015. PMID: 26516958 Review.
-
Rifapentine for the treatment of pulmonary tuberculosis.Clin Infect Dis. 2006 Dec 1;43(11):1468-75. doi: 10.1086/508278. Epub 2006 Oct 24. Clin Infect Dis. 2006. PMID: 17083024 Review.
Cited by
-
New developments in tuberculosis diagnosis and treatment.Breathe (Sheff). 2022 Mar;18(1):210149. doi: 10.1183/20734735.0149-2021. Epub 2021 Mar 8. Breathe (Sheff). 2022. PMID: 35284018 Free PMC article. Review.
-
Distinct blood transcriptomic signature of treatment in latent tuberculosis infected individuals at risk of developing active disease.Tuberculosis (Edinb). 2021 Dec;131:102127. doi: 10.1016/j.tube.2021.102127. Epub 2021 Sep 14. Tuberculosis (Edinb). 2021. PMID: 34555657 Free PMC article.
-
Efficacy and safety of different regimens in the treatment of patients with latent tuberculosis infection: a systematic review and network meta-analysis of randomized controlled trials.Arch Public Health. 2023 May 5;81(1):82. doi: 10.1186/s13690-023-01098-z. Arch Public Health. 2023. PMID: 37143101 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
